Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has initiated a Phase 1 single ascending dose escalation study of TNX-1500 in healthy volunteers. The study aims to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous TNX-1500.
August 16, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has initiated a Phase 1 trial of TNX-1500, which could potentially lead to positive outcomes for the company if the trial is successful.
The initiation of a Phase 1 trial is a significant step in the development of a new drug. If the trial is successful, it could potentially lead to further trials and eventually to the approval and marketing of the drug, which would have a positive impact on the company's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100